A. Gonçalves

Model‐informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID‐19

C. Rayner, R. Krishna, M. Dodds, 2020, British journal of clinical pharmacology.

Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load

A. Perelson, X. de Lamballerie, R. Ke, 2020, CPT: pharmacometrics & systems pharmacology.

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

X. de Lamballerie, B. Hoen, B. Lina, 2020, Nature.

What drives the dynamics of HBV RNA during treatment?

J. Guedj, V. Cosson, Yuyan Jin, 2020, Journal of viral hepatitis.

Model‐informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID‐19

C. Rayner, R. Krishna, M. Dodds, 2020, British journal of clinical pharmacology.

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

M. V. van Breemen, D. Montefiori, R. Sanders, 2021, Nature Communications.

Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS‐CoV‐2

C. Rayner, K. Patel, C. Kirkpatrick, 2020, British journal of clinical pharmacology.

Reply to: ‘Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action’

J. Guedj, A. Lemenuel-diot, A. Gonçalves, 2021, Journal of viral hepatitis.